EDAP TMS S.A.
As of Oct 22, 2026, EDAP TMS is in Stage 4, the downtrend phase, now in its first week (since Oct 19, 2026). It closed at $4.15, 34.5% below its 52-week high and below its 200-day average, which is rising.
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical dev… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is FOCL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
FOCL among Medical Distribution1st of 11 by relative strength
All 11 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | FOCL | Stage 4 · wk 1 | 92 | −12.4% |
| 2 | CAH | Stage 2 · wk 1 | 90 | +15.8% |
| 3 | HSIC | Stage 3 · wk 1 | 79 | +1.1% |
| 4 | MCK | Stage 2 · wk 7 | 76 | +15.0% |
| 5 | COR | Stage 2 · wk 4 | 58 | +8.4% |
| 6 | AHG | Stage 4 · wk 16 | 36 | +58.4% |
| 7 | YI | Stage 4 · wk 16 | 32 | −17.3% |
| 8 | COSM | Stage 1 · wk 7 | 13 | −37.8% |
EDAP TMS: quick answers
What stage is EDAP TMS in?
As of Oct 22, 2026, EDAP TMS (FOCL) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 19, 2026 and is in its first week there. What the four stages mean
Is EDAP TMS in an uptrend?
No. EDAP TMS is in a Stage 4 downtrend. It trades 5.7% below its 200-day average, which is rising.
How far is EDAP TMS from its 52-week high?
EDAP TMS closed at $4.15 on Oct 22, 2026, 34.5% below its 52-week high of $6.34. Its 52-week low is $1.81.
How has EDAP TMS performed over the past year?
As of Oct 22, 2026, EDAP TMS is up 75.1% over the past year and up 22.1% so far in 2026.
Which sector and industry is EDAP TMS in?
EDAP TMS is in the Medical Distribution industry, part of the Health Care sector.
About this companyHealth Care· Medical Distribution
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.